SCHEMBL26359118

SCHEMBL26359118

BN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(Nc4nc(-c5cccnc5)cs4)c3)cc2)CC1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 18/20 0.87
BCR P11274 15/20 0.87
KIT P10721 11/20 0.87
PDGFRA P16234 5/20 0.87
ABL2 P42684 4/20 0.87
PDGFRB P09619 3/20 0.87
EGFR P00533 2/20 0.87
ERBB2 P04626 2/20 0.87
LCK P06239 2/20 0.87
FYN P06241 2/20 0.87
CSF1R P07333 2/20 0.87
LYN P07948 2/20 0.87
FGR P09769 2/20 0.87
SRC P12931 2/20 0.87
BRAF P15056 2/20 0.87
NQO2 P16083 2/20 0.87
EPHA8 P29322 2/20 0.87
FRK P42685 2/20 0.87
BLK P51451 2/20 0.87
DDR1 Q08345 2/20 0.87

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Masitinib SCHEMBL29355443 0.93 ABL1 (1.00) ABL1BCRKITPDGFRAABL2
Masitinib SCHEMBL29353195 0.93 ABL1 (1.00) ABL1BCRKITPDGFRAABL2
SCHEMBL16085058 0.93 ABL1 (0.89) ABL1BCRKITPDGFRAABL2
Masitinib SCHEMBL717239 0.93 ABL1 (1.00) ABL1BCRKITPDGFRAABL2
SCHEMBL717173 0.93 ABL1 (0.88) ABL1BCRKITPDGFRAABL2
SCHEMBL717184 0.92 ABL1 (0.87) ABL1BCRKITPDGFRAABL2
SCHEMBL17177780 0.91 ABL1 (0.88) ABL1BCRKITPDGFRAABL2
SCHEMBL27386747 0.91 ABL1 (0.85) ABL1BCRKITPDGFRAABL2
SCHEMBL19236040 0.91 ABL1 (0.85) ABL1BCRKITPDGFRAABL2
SCHEMBL715940 0.91 ABL1 (0.85) ABL1BCRKITPDGFRAABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230302144-A1 Porphyrin Compounds and Compositions Useful for Treating Cancer ONCOSELECT THERAPEUTICS, LLC (US) 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230302144-A1 Porphyrin Compounds and Compositions Useful for Treating Cancer KIT, HCCS, PPIF ABL1 692/4885BCR 277/4885KIT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.